title: Development of fixed dose combination tablets containing zidovudine and lamivudine for paediatric applications.
abstract: In view of the lack of suitable paediatric antiretroviral formulations on the market, a novel fixed dose combination (FDC) tablet containing 300mg zidovudine (AZT) and 160mg lamivudine (3TC) was developed to improve dosing accuracy and allow flexible drug dosing in function of the body weight of paediatric HIV patients as recommended by WHO. Rectangular tablets with multiple fraction bars were designed and each tablet can be broken into 8 subunits, each subunit containing a drug dose corresponding to a body weight of 5kg. These fast-disintegrating subunits can easily be administered to children after dispersion in a liquid or mixing with food. In vitro quality control of the FDC tablets was determined and a crossover bioavailability study using 18 adult volunteers was performed after oral administration of the novel FDC tablet and a Duovir tablet. The results of the study showed that the novel tablets as well as its subunits disintegrated fast (<20s). After 30min dissolution, AZT and 3TC released from Duovir and the novel tablets was above 95%, the similarity factors f2 were above 50 for both AZT and 3TC. A tablet breakability test showed low weight variability (125.1+/-5mg, R.S.D.=4.4%), with limited weight loss (0.3%). There was no significant difference in pharmacokinetic parameters (C(max), t(max) and AUC(0-12h) values) between Duovir and the novel tablets formulated for paediatric applications.
authors.affiliation: Department of Pharmacy, National University of Rwanda, Butare, Rwanda.
authors.forename: E
authors.initials: E
authors.lastname: Kayitare
authors.forename: C
authors.initials: C
authors.lastname: Vervaet
authors.forename: J D
authors.initials: JD
authors.lastname: Ntawukulilyayo
authors.forename: B
authors.initials: B
authors.lastname: Seminega
authors.forename: Van
authors.initials: V
authors.lastname: Bortel
authors.forename: J P
authors.initials: JP
authors.lastname: Remon
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001682:Biological Availability; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004339:Drug Compounding; D005260:Female; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D010372:Pediatrics; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D012995:Solubility; D013607:Tablets; D015215:Zidovudine / Q000008:administration & dosage / Q000493:pharmacokinetics*
chemical_list: D019380:Anti-HIV Agents; D004338:Drug Combinations; D018894:Reverse Transcriptase Inhibitors; D013607:Tablets; D019259:Lamivudine; D015215:Zidovudine